Pharmaceutical M&A has been reshaping the competitive landscape at a pace and scale unmatched in any other sector. Pfizer’s $43 billion acquisition of Seagen in 2023 was the largest pharmaceutical transaction in a decade. Merck acquired Prometheus Biosciences for $10.8 billion entering the IBD biologics market. The strategic logic driving pharmaceutical M&A in 2023-2026 is dominated by the $300 billion patent cliff requiring revenue replacement at unprecedented scale, rapid advance of new drug modalities creating acquisition opportunities, and the biotech funding drought creating a window of reduced valuations for clinical-stage assets.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Major Transactions
• Most Active Acquirers
• Divestiture Activity
• Valuation Analysis
• Biotech Ecosystem as Acquisition Pipeline
• M&A Pipeline 2026-2027
Table of Contents
1. Executive Summary
2. Market Overview
3. Major Transactions
4. Most Active Acquirers
5. Divestiture Activity
6. Valuation Analysis
7. Biotech Ecosystem as Acquisition Pipeline
8. M&A Pipeline 2026-2027
9. Competitive Landscape
10. Regional Market Analysis
11. Strategic Conclusions and Recommendations
12. Appendix
List of Tables
Table 1. Pharmaceutical M&A Transactions — Complete List 2023-2026
Table 2. Transactions Over $1 Billion — Detailed Analysis
Table 3. Valuation Multiples by Therapeutic Area 2020-2025
Table 4. Most Active Acquirers — Transaction Volume and Value
Table 5. Divestiture Activity — Portfolio Rationalization 2023-2025
Table 6. Biotech Acquisition Pipeline — Most Likely Targets 2026-2027
Table 7. M&A Valuation by Modality 2025
Table 8. M&A Pipeline — Most Likely Transactions 2026-2027
Table 9. Strategic Gap Analysis by Company
Table 10. Key Risks and Mitigation Strategies
Companies Profiled
Pfizer
Merck
AbbVie
Bristol-Myers Squibb
Johnson & Johnson
Roche
Novartis
AstraZeneca
Sanofi
Eli Lilly
